Enhanced Algorithm for Crohn's Treatment Incorporating Early Combination Therapy

Launched by ALIMENTIV INC. · Sep 28, 2012

Keywords

ClinConnect Summary

Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract. During disease exacerbations, pharmacological or surgical intervention is usually needed to re-establish remission. Ideally, strategies should be employed to maintain patients in long-term remission while minimizing exposure to corticosteroids and reduce therapy-related toxicity.

Nevertheless, in reality many patients with CD do not receive effective therapy and their disease often remains active, leading to uncontrolled inflammation and complications from either the underlying disease or corticosteroids.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Documented diagnosis of CD
• • Written informed consent must be obtained and documented.
• • Willing to utilize study supply of adalimumab provided in syringe format, if indicated according to treatment algorithm.
• Exclusion Criteria:
• • Any conditions (e.g., history of alcohol or substance abuse) which, in the opinion of the investigator, may interfere with the patient's ability to comply with study procedures.
• • Latex allergy or other conditions in which adalimumab syringes are contraindicated
• • Currently participating, or planning to participate in a study involving investigational product within 24 months that may interfere with the patient's ability to comply with study procedures.
• • Previously failed all classes of tumor necrosis factor (TNF) antagonists for the treatment of CD.
• • Diagnosis of short bowel syndrome